Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia

  • Authors:
    • Bertil Uggla
    • Elisabet Tina
    • Hareth Nahi
    • Christer Paul
    • Martin Höglund
    • Allan Sirsjö
    • Ulf Tidefelt
  • View Affiliations

  • Published online on: July 1, 2007     https://doi.org/10.3892/ijo.31.1.153
  • Pages: 153-160
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of this study was to correlate the expression of topoisomerase (topo) IIα to in vitro drug sensitivity and to the clinical outcome in patients with acute leukaemia. Leukaemic cells were isolated from bone marrow or blood from 94 patients. Topo IIα mRNA (n=58) and protein (n=60) expression was determined by real-time RT-PCR and flow cytometry, respectively. In both groups, chemosensitivity testing by a bioluminescence ATP assay was performed to a variable extent for both topo IIα poisons and non-topo IIα targeting drugs. Topo IIα mRNA expression varied with relative values ranging from 0.03 to 14.20 (median 1.10). The median value for topo IIα protein-positive cells was 23% (range 0-99%). Cell samples from patients with a high (>median value) percentage of topo IIα-positive cells were significantly more sensitive to the topo IIα active drugs etoposide and daunorubicin, and showed a borderline value for idarubicin (p=0.08), while there was no difference for non-topo IIα targeting drugs. However, we did not find any significant differences in mRNA expression or the percentage of topo IIα-positive cells in patients who achieved complete remission after at most two induction courses compared with those who did not, nor did we find any difference in survival when patients with high mRNA expression/percentage of topo IIα-positive cells were compared with patients with low values. We conclude that expression of topo IIα, determined as percentage of topo IIα-positive cells, in leukaemic cells correlates to chemosensitivity in vitro against topoisomerase poisons but that it does not predict clinical outcome in acute leukaemia.

Related Articles

Journal Cover

July 2007
Volume 31 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Uggla B, Tina E, Nahi H, Paul C, Höglund M, Sirsjö A and Tidefelt U: Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. Int J Oncol 31: 153-160, 2007.
APA
Uggla, B., Tina, E., Nahi, H., Paul, C., Höglund, M., Sirsjö, A., & Tidefelt, U. (2007). Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia. International Journal of Oncology, 31, 153-160. https://doi.org/10.3892/ijo.31.1.153
MLA
Uggla, B., Tina, E., Nahi, H., Paul, C., Höglund, M., Sirsjö, A., Tidefelt, U."Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia". International Journal of Oncology 31.1 (2007): 153-160.
Chicago
Uggla, B., Tina, E., Nahi, H., Paul, C., Höglund, M., Sirsjö, A., Tidefelt, U."Topoisomerase IIα mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia". International Journal of Oncology 31, no. 1 (2007): 153-160. https://doi.org/10.3892/ijo.31.1.153